Chronic Kidney Disease Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

Chronic Kidney Disease Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

The chronic kidney disease market is expected to register a CAGR of 6.6% during the forecast period 2022-2027.

The increasing cases of COVID-19 have a direct correlation with the growth of kidney-related diseases. For instance, as per a report published in 2021, titled, "Acute Kidney Injury in COVID-19: 90 Days of the Pandemic in a Brazilian Public Hospital," 4–37% of COVID-19 cases involve the kidneys, and acute kidney diseases have an incidence of 50% among hospitalized COVID-19 patients. Thus, it has been found that the COVID-19 virus is having an impact on the kidney of patients, which in turn, is expected to increase the burden of kidney disorders in the near future and fuel the market growth.

The major factors for the growth of the chronic kidney disease market include the increasing incidence of chronic kidney diseases, technological advancements in diagnostic tests for kidney diseases, and the increasing need for early detection.

Chronic kidney disease (CKD) is a condition that causes reduced kidney function over a period of time. It may develop over many years and lead to end-stage kidney (or renal) disease (ESRD). It has become an enormous public health issue. For instance, as per a 2019 report by the Center for Disease Control and Prevention, 15% of adults in United States, amounting to approximately 37 million people, are estimated to have CKD.

In 2020, as per data released on World Kidney Day, a joint initiative of the International Society of Nephrology (ISN) and the International Federation of Kidney Foundations (IFKF), kidney disease affected around 850 million people globally. As per estimates, one in ten adults has chronic kidney disease (CKD). The global burden of CKD is continuously increasing and is projected to become the 5th most common cause of years of life lost globally by 2040.

Immunotherapy has been gaining the attention of many companies and has been observed as one of the most effective treatments for kidney cancer, especially renal cell carcinoma. In March 2021, around USD 50 million was approved for the research of kidney cancer by the Department of Defense’s Congressionally Directed Medical Research Programs (CDMRP), with a federal budget for research funding in United States. Thus, a high number of cases of chronic kidney diseases coupled with technological advancements are expected to boost the demand for the diagnosis and treatment of products and lead to the high growth of the market.

The major test for the diagnosis of kidney disease includes a blood test, and it helps understand how well the kidneys are working. The blood test measures levels of a waste product called creatinine in the blood. The glomerular filtration rate (eGFR) is calculated to evaluate the milliliters of waste that the kidney is able to filter in a minute.

Moreover, the demand for these tests is expected to increase as the incidence of CKD is high and growing in many parts of the world. The global prevalence of end-stage renal diseases (ESRD) is high and increasing at a significant rate. On World Kidney Day, a joint initiative of the International Society of Nephrology (ISN) and the International Federation of Kidney Foundations (IFKF) in 2020, it was stated that currently, around 850 million people globally suffer from a kidney disorder, and it is expected to become the 5th most common cause of years of life lost globally by 2040.

Additionally, in 2020, a report published by Kidney Foundation stated that around 4 million people have kidney disease in Canada, of which 46% of new patients are under the age of 65. Additionally, the number of people living with end-stage kidney disease has grown by 35% since 2009. Hence, owing to the rising prevalence of chronic kidney diseases, the market is expected to witness high growth over the forecast period.

North America held the largest market share in previous years and is anticipated to do the same over the forecast period. The major factors driving the growth of the market in United States include developed healthcare infrastructure and increased government initiatives, which offer lucrative reimbursement policies in the country. According to the estimates of the American Cancer Society, in 2020, there were around 73,750 new cases of kidney cancer in United States and approximately 14,830 deaths from this disease.

As per the same source, kidney cancer is among the ten most common cancers in both men and women. Overall, the lifetime risk for developing kidney cancer in men is about 1 in 46 (2.02%). The lifetime risk for women is about 1 in 82 (1.02%).

This indicates high potential market demand for kidney disease diagnostics and therapeutics. Owing to the rapid increase in the incidence and prevalence of kidney diseases, the market in United States is expected to grow over the coming years. The market players are also focusing on launching new products in the market. For instance, in 2019, the US Food and Drug Administration (FDA) approved the Janssen Pharmaceutical’s drug INVOKANA (Canagliflozin) to reduce the risk of end-stage kidney disease and cardiovascular events in patients with Type 2 diabetes and chronic kidney disease.

Also, in March 2020, the FDA granted fast track designation for investigation of the Boehringer Ingelheim and Eli Lilly Alliance’s SGLT2 inhibitor empagliflozin to reduce the risks for renal disease progression and cardiovascular death in adults with chronic kidney disease, according to a press release from Boehringer Ingelheim and Eli Lilly. Thus, the presence of these factors is anticipated to offer lucrative growth to the regional market.

The market studied is fragmented, owing to the presence of many major players. Some of the market players are Abbott Laboratories, Amgen Inc., AstraZeneca PLC, Beckman Coulter, F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Pfizer Inc., Siemens Healthineers, Sysmex Corporation, and Teva Pharmaceutical Industries Ltd.

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support